[go: up one dir, main page]

TW200628162A - Combination treatment for multiple sclerosis - Google Patents

Combination treatment for multiple sclerosis

Info

Publication number
TW200628162A
TW200628162A TW094144640A TW94144640A TW200628162A TW 200628162 A TW200628162 A TW 200628162A TW 094144640 A TW094144640 A TW 094144640A TW 94144640 A TW94144640 A TW 94144640A TW 200628162 A TW200628162 A TW 200628162A
Authority
TW
Taiwan
Prior art keywords
multiple sclerosis
combination treatment
cda
alpha
agent
Prior art date
Application number
TW094144640A
Other languages
Chinese (zh)
Other versions
TWI373337B (en
Inventor
Luca Giampiero De
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of TW200628162A publication Critical patent/TW200628162A/en
Application granted granted Critical
Publication of TWI373337B publication Critical patent/TWI373337B/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention is directed towards treatments for multiple sclerosis comprising administering to a patient in need thereof a first agent, such as 2- chloro-2'-deoxyadenosine (2-CdA), that reduces the number of lymphocytes in combination with a second agent, such as an anti-alpha-4 integrin antibody, that blocks the adhesion of monocytes and leukocytes to endothelial cells. The use of 2-CdA combined with an anti-alpha-4 integrin antibody may be more effective than either treatment alone for MS. Furthermore, the combination treatment may allow for a lowering or altering the dose of one or more of the agents in order to limit any adverse effects associated with the individual agents, but maintaining the same therapeutic efficacy.
TW94144640A 2004-12-22 2005-12-16 Combination treatment for multiple sclerosis TWI373337B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63867404P 2004-12-22 2004-12-22

Publications (2)

Publication Number Publication Date
TW200628162A true TW200628162A (en) 2006-08-16
TWI373337B TWI373337B (en) 2012-10-01

Family

ID=37908522

Family Applications (1)

Application Number Title Priority Date Filing Date
TW94144640A TWI373337B (en) 2004-12-22 2005-12-16 Combination treatment for multiple sclerosis

Country Status (3)

Country Link
AR (1) AR052831A1 (en)
MY (1) MY143861A (en)
TW (1) TWI373337B (en)

Also Published As

Publication number Publication date
AR052831A1 (en) 2007-04-04
MY143861A (en) 2011-07-15
TWI373337B (en) 2012-10-01

Similar Documents

Publication Publication Date Title
BR9911076A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C
NO332893B1 (en) Use of antibody for the preparation of drug for use in CVP chemotherapy
MXPA05013642A (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer.
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
WO2002069904A3 (en) Cd2 antagonists for treatment of autoimmune or inflammatory disease
FR2869231B1 (en) THERAPEUTIC COMPOSITION CONTAINING AT LEAST ONE PYRROLOBENZODIAZEPINE DERIVATIVE AND FLUDARABINE
PH12014500833A1 (en) Methods for treating hcv
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
MXPA02011099A (en) Delivery devices for treatment of vascular disease.
BRPI0516531A (en) autoimmune disorders immunotherapy
DE60114406D1 (en) ACTIVE AGGREGATION SYSTEMS FOR THE TREATMENT OF VASCULAR DISEASES
DE60036915D1 (en) USE OF HYALURONAN FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING THE EFFICACY OF CYTOTOXIC DRUGS
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UA99094C2 (en) Method for the treatment of patients with autoantibody positive disease
JP2003528919A5 (en)
BR0317539A (en) Methods and compositions for treating herpes virus infections using selective cyclooxygenase-2 inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
NO20073635L (en) Combination therapy for multiple sclerosis
TW200628162A (en) Combination treatment for multiple sclerosis
WO2025049814A3 (en) Ribonucleotide reductase (rnr) compositions and methods of use
El Jurdi et al. Phase II study of myeloablative 7-8/8-matched allotransplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees